Vaxcyte (NASDAQ:PCVX) Earns “Buy” Rating from BTIG Research

Vaxcyte (NASDAQ:PCVX)‘s stock had its “buy” rating reissued by investment analysts at BTIG Research in a research note issued to investors on Monday,Benzinga reports. They presently have a $85.00 price objective on the stock. BTIG Research’s price objective suggests a potential upside of 86.16% from the company’s previous close.

PCVX has been the subject of a number of other reports. The Goldman Sachs Group assumed coverage on Vaxcyte in a research report on Friday, September 12th. They issued a “neutral” rating and a $38.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Tuesday, October 14th. Finally, Cowen reissued a “buy” rating on shares of Vaxcyte in a research note on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vaxcyte currently has an average rating of “Moderate Buy” and an average target price of $102.00.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $45.66 on Monday. The firm has a 50 day simple moving average of $38.62 and a 200 day simple moving average of $35.18. Vaxcyte has a fifty-two week low of $27.66 and a fifty-two week high of $103.30. The firm has a market cap of $5.98 billion, a P/E ratio of -9.43 and a beta of 1.07.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same quarter in the previous year, the company posted ($0.83) earnings per share. On average, sell-side analysts expect that Vaxcyte will post -4.21 EPS for the current year.

Institutional Trading of Vaxcyte

Large investors have recently made changes to their positions in the company. AlphaQuest LLC bought a new position in Vaxcyte during the first quarter worth about $33,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Vaxcyte during the first quarter worth about $35,000. CWM LLC raised its position in shares of Vaxcyte by 197.3% during the second quarter. CWM LLC now owns 1,680 shares of the company’s stock worth $55,000 after purchasing an additional 1,115 shares during the period. IFP Advisors Inc lifted its holdings in shares of Vaxcyte by 376.4% during the 1st quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock valued at $62,000 after purchasing an additional 1,306 shares in the last quarter. Finally, Blue Trust Inc. grew its position in shares of Vaxcyte by 176.7% in the 2nd quarter. Blue Trust Inc. now owns 2,161 shares of the company’s stock valued at $70,000 after purchasing an additional 1,380 shares during the period. Institutional investors own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.